Combining CCK with other hormones such as GLP-1, amylin, or leptin shows promise for synergistic effects in treating obesity and T2DM, highlighting the therapeutic potential of CCK-based strategies [133]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.